Form 3 Filing for Apellis Pharmaceuticals, Inc.

This filing concerns Apellis Pharmaceuticals, Inc. and details a Tender and Support Agreement entered into on March 31, 2026. Biogen Inc. may be considered part of a "group" that beneficially owns over 10% of the outstanding Common Stock through this agreement. However, the agreement does not grant Biogen Inc. a pecuniary interest in the Common Stock, thus it is not considered a beneficial owner for Section 16 of the Exchange Act. The filing also addresses Restricted Stock Units (RSUs) and stock options held by other parties, clarifying that Biogen Inc. does not have a pecuniary interest in these underlying securities and is not a beneficial owner in relation to them.